Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KeraStat Gel
- Development stage
- Unknown
- Lead developer
- KeraNetics
- Modality
- Recombinant Proteins and Enzymes, Hydrogel Systems → Drug Delivery Systems
- Administration
- Topical
01
Overview
KeraStat Gel is a keratin-based hydrogel wound dressing developed by KeraNetics. It is composed of human-derived keratin proteins (specifically alpha-keratins) and is designed to manage various types of wounds, including partial-thickness burns, radiation dermatitis, and surgical wounds. The gel provides a moist wound environment and a protein-rich scaffold that supports cellular migration and re-epithelialization. It has been evaluated in clinical trials for its ability to improve cosmetic outcomes and speed up healing compared to standard treatments like silver sulfadiazine. While it is regulated as a medical device, its therapeutic effect is derived from the biological properties of the keratin proteins.
- Brand names
- KeraStat Gel
- Other names
- KeraStat
Beyond the preview
Go deeper on KeraStat Gel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KeraStat Gel.